Fox Chase Study Reveals Mechanism for Repairing DNA Damage Caused by Environmental Triggers
December 2nd 2022It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers.
Immune Checkpoint Inhibitors at ASCO: Long-term Efficacy Data Mount
July 25th 2022Twelve years after key research into immune checkpoint inhibitor therapy first made a splash at the American Society of Clinical Oncology Annual Meeting, evidence continues to mount that supports the durability of these agents in a range of cancers.
Fox Chase Cancer Center Experts Highlight the Growing Treatment Landscapes in Lung Cancer
Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.
Nivolumab Plus Axitinib Generates Promising Responses in Untreated Advanced RCC
The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.
What Can Residents Learn From an Oncology Fellowship?
November 25th 2021Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what the benefits are of an oncology fellowship and the takeaways and important lessons Nardello learned from his own breast oncology fellowship at Fox Chase Cancer Center.
Why Should Someone Pursue a Fellowship in Oncology?
November 25th 2021Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what brought Dr. Nardello to the breast cancer field, what made him decide to pursue an oncology fellowship, and what residents should think about when choosing a fellowship location.